Fycompa perampanel regulatory update

FDA approved an sNDA from Eisai for Fycompa perampanel as an adjunctive therapy to treat primary generalized tonic-clonic seizures in epileptics ages >=12. The AMPA-type glutamate receptor antagonist ...